To Örebro University

oru.seÖrebro University Publications
System disruptions
We are currently experiencing disruptions on the search portals due to high traffic. We are working to resolve the issue, you may temporarily encounter an error message.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Antibiotic Therapy and Risk of Early-Onset Colorectal Cancer: A National Case-Control Study
Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston Massachusetts, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston Massachusetts, USA.
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis Missouri, USA; Siteman Cancer Center, Washington University School of Medicine, St Louis Missouri, USA.
SDS Life Science AB, Danderyd, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2022 (English)In: Clinical and Translational Gastroenterology, E-ISSN 2155-384X, Vol. 13, no 1, article id e00437Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: Antibiotic use has emerged as a risk factor for colorectal neoplasia and is hypothesized as a contributor to the rising incidence of colorectal cancer under age 50 years or early-onset colorectal cancer (EOCRC). However, the impact of antibiotic use and risk of EOCRC is unknown.

METHODS: We conducted a population-based case-control study of CRC among individuals aged >= 18 years in the Epidemiology Strengthened by histoPathology Reports in Sweden (ESPRESSO) cohort (2006-2016). The primary outcome was EOCRC. A secondary outcome was CRC at any age. Incident CRC was pathologically confirmed, and for each, up to 5 population-based controls were matched on age, sex, county of residence, and calendar year. We assessed prescriptions until 6 months before CRC diagnosis. Conditional logistic regression was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs).

RESULTS: We identified 54,804 cases of CRC (2,557 EOCRCs) and 261,089 controls. Compared with none, previous antibiotic use was not associated with EOCRC risk after adjustment for potential confounders (aOR 1.06, 95% CI: 0.96, 1.17) with similarly null findings when stratified by anatomic tumor site. In contrast, previous antibiotic use was weakly associated with elevated risk for CRC at any age (aOR 1.05, 95% CI: 1.02, 1.07). A potential but modest link between broad-spectrum antibiotic use and EOCRC was observed (aOR 1.13, 95% CI: 1.02, 1.26).

DISCUSSION: We found no conclusive evidence that antibiotics are associated with EOCRC risk. Although antibiotic use was weakly associated with risk of CRC at any age, the magnitude of association was modest, and the study period was relatively short.

Place, publisher, year, edition, pages
Nature Publishing Group, 2022. Vol. 13, no 1, article id e00437
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-97608DOI: 10.14309/ctg.0000000000000437ISI: 000751955300017PubMedID: 35029165Scopus ID: 2-s2.0-85124437722OAI: oai:DiVA.org:oru-97608DiVA, id: diva2:1639372
Note

Funding agencies:

Janssen Corporation

United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) K23DK125838  

American Gastroenterological Association

Crohn's and Colitis Foundation

United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI) R01CA202704  R35 CA253185  R00CA215314  

American Cancer Society MRSG-17-220-01-NEC

General Electric

 

Available from: 2022-02-21 Created: 2022-02-21 Last updated: 2025-02-11Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Ludvigsson, Jonas F.

Search in DiVA

By author/editor
Ludvigsson, Jonas F.
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Clinical and Translational Gastroenterology
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 35 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf